Hepatosplenic T-Cell lymphoma in a young man with Crohn's disease: Case report and literature review

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 2, 2010, Pages 144-148

  Ochenrider, Mark G ^a   Patterson, David J ^b   Aboulafia, David M ^c,d  

^a Division of Internal Medicine   (United States)

^b Division of Gastroenterology   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adalimumab; Immunosuppression; Infliximab; Pentostatin; Thiopurines; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; BUSULFAN; CARBOPLATIN; CD16 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INFLIXIMAB; LACTATE DEHYDROGENASE; MERCAPTOPURINE; MESALAZINE; PENTOSTATIN; PREDNISONE; THIOPURINE METHYLTRANSFERASE; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CYTOPENIA; DIARRHEA; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLOW CYTOMETRY; HEMATOCRIT; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; POLYMORPHONUCLEAR CELL; RETICULOCYTE; SCHOOL CHILD; SPLENOMEGALY; SURVIVAL TIME; T CELL LYMPHOMA; THROMBOCYTE; TREATMENT DURATION; WEIGHT REDUCTION; CANCER PATIENT; CD3+ T LYMPHOCYTE; GASTROINTESTINAL SYMPTOM; GENE REARRANGEMENT; HYPERPLASIA; PALLIATIVE THERAPY; REVIEW; T LYMPHOCYTE RECEPTOR GENE; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; FATALITY; LIVER TUMOR; PERIPHERAL T CELL LYMPHOMA; SPLEEN TUMOR; T CELL LEUKEMIA;

6-MERCAPTOPURINE; ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AZATHIOPRINE; CROHN DISEASE; FATAL OUTCOME; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LIVER NEOPLASMS; LYMPHOMA, T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; MALE; SPLENIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954390990     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.021     Document Type: Article

References (24)

1. Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-Cell lymphoma: sinusal/ sinusoidal localization of malignanT Cells expressing the T-Cell receptor gamma delta. Blood 1990;75:2213-9.
2. Suarez F, Wlodarska I, Rigal-Huguet F, et al. Hepatosplenic alphabeta T-Cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-Cell lymphoma. Am J Surg Pathol 2000;24:1027-32.
3. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer;2001.
4. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-Cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
5. Lémann M, de La Valussiére G, Bouhnick Y, et al. Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): long-term follow up of patients. Gastroenterology 1998;114(suppl 1):A1020.
6. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003;44:531-3.
7. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-Cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40:220-2.
8. Mittal S, Milner BJ, Johnston PW, et al. A case of hepatosplenic gamma-delta T-Cell lymphoma with a transient response to fludarabine and alemtuzumab. EurJ Haematol 2006;76:531-4.
9. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T Cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
10. Zeidan A, Sham R, Shapiro J, et al. Hepatosplenic T-Cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma 2007;48:1410-3.
11. Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T Cell lymphoma in inflammatory bowel disease. Gut 2008;57:1639-41.
12. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-Cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.Blood 2003;102:4261-9.
13. Drini M, Prichard PJ, Brown GJ, et al. Hepatosplenic T-Cell lymphoma following infliximab therapy for Crohn's disease. Med J Aust 2008;189:464-5.
14. Humphreys MR, Cino M, Quirt I, et al. Long-term survival in two patients with hepatosplenic T Cell lymphoma treated with interferon-alpha. Leuk Lymphoma 2008;49:1420-3.
15. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T-Cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009;48:386-8.
16. Beaugerie L, Carrat F, Bouvier AM, et al. 818 Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the Cesame cohort. Gastroenterology 2008;134(suppl 1):A116.
17. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58:1427-36.
18. Tey SK, Marlton PV, Hawley CM, et al. Post-transplant hepatosplenic T-Cell lymphoma successfully treated with HyperCVAD regimen. Am J Hematol 2008;83:330-3.
19. François A, Lesesve JF, Stamatoullas A, et al. Hepatosplenic gamma/delta T-Cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am J Surg Pathol 1997;21:781-90.
20. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
21. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
22. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
23. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
24. Centocor Ortho Biotech Inc. New one-year data from REMICADE®SONIC trial show sustained efficacy compared with azathioprine in treatment of Crohn's disease [Web site]. Medical News Todays 2009 Accessed: February 9, 2010. Available at: www.medicalnewstoday.com/articles/152322.php.